Z. Goodman

Epidemiology · 2001–2019

A researcher in the Science corpus: 15 papers; trusts 2 researchers and is trusted by 1 researcher here, as inferred from the citation graph.

Subfields

Whom Z. Goodman trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. D. Kleiner
  2. G. Garcia‐Tsao
  3. E. Brunt

Who trusts Z. Goodman overall

  1. S. Friedman

Papers from Z. Goodman's perspective

Ordered by how strongly the researchers Z. Goodman trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Long‐term follow‐up of patients with NAFLD and elevated liver enzymes (Hepatology)
  2. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. (Journal of Hepatology)
  3. Design and validation of a histological scoring system for nonalcoholic fatty liver disease (Hepatology)
  4. Meta-analysis: Natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity (Annals medicus)
  5. NAFLD may be a common underlying liver disease in patients with hepatocellular Carcinoma in the United States (Hepatology)
  6. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. (Gastroenterology)
  7. Risk of Hepatocellular Carcinoma Across a Biological Gradient of Serum Hepatitis B Virus DNA Level
  8. Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease. (Journal of Hepatology)
  9. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. (New England Journal of Medicine)
  10. Histological outcome during long-term lamivudine therapy. (Gastroenterology)

Their papers